


Pharmaceutical Cost Reports

Fully Insured Individual and Group Coverage
(Excludes self-funded insured health groups)


2021 Q3 RX Summary by Generic, Brand, and Over the Counter

	Count	Percent Of Claims	Allowed Amt	% of Dollar Volume
Generic	3,704,308	77.75%	\$ 81,029,990.03	11.64%
Brand	1,024,520	21.50%	\$ 612,674,333.57	88.00%
OTC	35,463	0.74%	\$ 2,526,923.67	0.36%
	4,764,291		\$ 696,231,247.27	

Percent of Claims



Percent of Dollar Volume



2021 Q3 Top 10 Drug Categories

Drug Category	Charged	Allowed	Paid	Member Responsibility
Therapies for: Transplant Rejection, Arthritis, Autoimmune Diseases	\$ 95,114,471.47	\$ 71,975,260.21	\$ 68,319,550.70	\$ 2,951,097.87
Diabetic Therapies	\$ 93,967,890.52	\$ 70,209,299.08	\$ 61,564,114.13	\$ 8,581,399.06
Cancer Therapies	\$ 43,854,120.01	\$ 26,996,013.08	\$ 25,844,588.98	\$ 947,814.58
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 31,285,204.42	\$ 21,424,299.05	\$ 18,626,005.19	\$ 2,761,509.92
Therapies for: Alcohol Dependence, ADHD/Mental Alertness, Appetite Suppression, Neuromuscular Abnormalities, Glaucoma, Increase Bladder/Intestinal Functions	\$ 23,323,623.55	\$ 15,134,573.43	\$ 11,585,449.56	\$ 3,523,964.82
Asthma/Breathing Therapies	\$ 19,921,741.55	\$ 14,678,231.37	\$ 12,248,103.41	\$ 2,419,935.32
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 17,124,912.25	\$ 12,948,833.80	\$ 10,669,276.45	\$ 2,276,761.13
Pain Therapies	\$ 30,003,539.32	\$ 11,882,292.34	\$ 9,813,660.63	\$ 2,011,408.42
Therapies for: Fertility, Contraceptives, Anemia, Osteoporosis, Weight Loss, Excessive Hair Growth, Uterine Bleeding, Hormone-Dependent Tumors	\$ 18,581,969.08	\$ 11,799,891.20	\$ 8,963,930.57	\$ 2,803,205.81
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 13,648,680.79	\$ 10,558,975.10	\$ 9,945,788.49	\$ 448,950.78

2021 Q3 Top 30 Drugs by Average Dollar Volume *

Trade Name	RX Type	Average Day Supply	Average Charged	Average Allowed	Average Paid	Average Member Responsibility
HAEGARDA C1 ESTERASE INHIBITOR SUBCUTANEOUS HUMAN	BRAND	28	\$ 84,701.20	\$ 58,602.44	\$ 57,995.73	\$ 206.71
KORLYM	BRAND	30	\$ 45,393.71	\$ 45,393.71	\$ 45,082.16	\$ 311.55
ADVATE	BRAND	28	\$ 84,016.73	\$ 37,308.54	\$ 36,994.91	\$ 253.94
HEMLIBRA	BRAND	28	\$ 57,850.11	\$ 32,259.27	\$ 32,037.97	\$ 166.32
FIRAZYR	BRAND	12	\$ 41,134.26	\$ 33,471.45	\$ 28,076.45	\$ 5,395.00
ORENITRAM	BRAND	30	\$ 45,901.80	\$ 25,845.44	\$ 25,745.44	\$ 100.00
TRIKAFTA	BRAND	27	\$ 29,317.21	\$ 24,498.17	\$ 24,235.37	\$ 252.81
KALYDECO	BRAND	28	\$ 27,809.83	\$ 23,493.78	\$ 23,294.52	\$ 199.26
SYMDEKO	BRAND	28	\$ 28,928.94	\$ 22,250.91	\$ 22,101.28	\$ 94.79
EPCLUSA	BRAND	28	\$ 28,067.16	\$ 22,375.66	\$ 21,930.73	\$ 444.94
ORKAMBI	BRAND	28	\$ 25,103.08	\$ 21,023.25	\$ 20,871.27	\$ 50.14
VYNDAMAX	BRAND	25	\$ 25,573.22	\$ 20,972.49	\$ 20,832.68	\$ 139.81
STELARA	BRAND	38	\$ 26,284.69	\$ 21,316.00	\$ 20,652.34	\$ 345.14
RETEVMO	BRAND	30	\$ 26,862.40	\$ 20,607.83	\$ 20,607.83	\$ -
TUKYSA	BRAND	30	\$ 27,156.42	\$ 20,167.72	\$ 20,150.03	\$ 17.69
UPTRAVI	BRAND	30	\$ 34,407.87	\$ 19,473.80	\$ 19,456.21	\$ 17.59
PALYNZIQ	BRAND	28	\$ 22,779.48	\$ 19,597.80	\$ 19,132.93	\$ 464.87
TYVASO	BRAND	28	\$ 27,756.14	\$ 19,154.70	\$ 19,035.47	\$ 85.19
CABOMETYX	BRAND	23	\$ 22,569.65	\$ 18,981.02	\$ 18,980.66	\$ 0.36
REMODULIN	BRAND	22	\$ 47,039.29	\$ 23,376.50	\$ 18,714.77	\$ 4,661.73
POMALYST	BRAND	27	\$ 22,306.55	\$ 17,821.30	\$ 17,691.78	\$ 94.81
SKYRIZI	BRAND	42	\$ 21,064.70	\$ 17,640.20	\$ 16,938.94	\$ 573.63
REVLIMID	BRAND	26	\$ 20,990.51	\$ 16,831.02	\$ 16,374.20	\$ 325.85
RUBRACA	BRAND	30	\$ 29,928.61	\$ 16,592.06	\$ 16,231.18	\$ 360.88
KUVAN	BRAND	30	\$ 19,474.97	\$ 16,970.71	\$ 15,852.38	\$ 579.87
JYNARQUE	BRAND	27	\$ 19,425.21	\$ 15,633.02	\$ 15,426.40	\$ 204.67
PROMACTA	BRAND	29	\$ 18,123.08	\$ 15,127.51	\$ 14,949.85	\$ 175.28
INLYTA	BRAND	30	\$ 19,815.30	\$ 15,776.40	\$ 14,887.59	\$ 108.87

XYREM	BRAND	29	\$ 16,951.64	\$ 15,302.44	\$ 14,747.10	\$ 555.34
AFINITOR	BRAND	25	\$ 18,937.12	\$ 14,695.88	\$ 14,693.45	\$ 2.44

*To be included in this table, at least 20 prescriptions for the drug must exist in the database.

2021 Q3 Top 30 Drugs by Total Dollar Volume *

TradeName	RX Type	Total Charged	Total Allowed	Total Paid	Total Member Responsibility
HUMIRA	BRAND	\$ 82,059,687.41	\$ 66,335,166.82	\$ 62,698,491.01	\$ 3,203,071.94
STELARA	BRAND	\$ 37,271,694.97	\$ 30,226,083.71	\$ 29,285,015.08	\$ 489,411.56
ATORVASTATIN CALCIUM	GENERIC	\$ 22,246,185.92	\$ 1,097,897.16	\$ 359,548.43	\$ 738,376.80
ENBREL	BRAND	\$ 19,745,431.65	\$ 16,136,433.50	\$ 15,096,135.90	\$ 1,022,921.54
OZEMPIC	BRAND	\$ 16,111,947.50	\$ 12,825,403.99	\$ 11,545,326.28	\$ 1,270,333.53
NORDITROPIN	BRAND	\$ 15,930,385.89	\$ 12,330,742.52	\$ 11,742,512.39	\$ 558,396.67
TRIKAFTA	BRAND	\$ 14,424,068.97	\$ 12,053,097.84	\$ 11,923,804.25	\$ 124,380.87
TRULICITY	BRAND	\$ 14,323,507.67	\$ 11,057,383.70	\$ 9,849,847.74	\$ 1,207,933.66
VYVANSE	BRAND	\$ 13,669,282.69	\$ 10,822,774.68	\$ 8,328,975.47	\$ 2,475,047.71
OTEZLA	BRAND	\$ 12,709,797.92	\$ 10,503,701.96	\$ 9,288,502.10	\$ 935,600.53
COSENTYX	BRAND	\$ 12,705,996.27	\$ 10,198,470.77	\$ 9,468,479.35	\$ 638,815.47
DUPIXENT	BRAND	\$ 12,483,654.19	\$ 10,129,550.36	\$ 8,769,723.19	\$ 1,170,465.63
ARIPIPIRAZOLE	GENERIC	\$ 12,229,030.96	\$ 331,824.90	\$ 167,261.24	\$ 164,778.28
OMEPIRAZOLE	GENERIC	\$ 12,188,579.40	\$ 561,194.25	\$ 79,347.95	\$ 481,333.71
BIKTARVY	BRAND	\$ 11,937,955.56	\$ 9,818,496.95	\$ 8,190,043.78	\$ 1,628,153.17
ROSUVASTATIN CALCIUM	GENERIC	\$ 11,753,221.11	\$ 479,105.19	\$ 196,543.98	\$ 282,594.53
JARDIANCE	BRAND	\$ 11,442,776.93	\$ 9,053,375.54	\$ 7,883,381.79	\$ 1,169,494.04
NOVOLOG	BRAND	\$ 10,994,641.75	\$ 8,232,556.38	\$ 7,425,306.59	\$ 768,821.73
ELIQUIS	BRAND	\$ 9,822,192.87	\$ 7,732,793.96	\$ 6,386,158.71	\$ 1,343,601.80
SKYRIZI	BRAND	\$ 9,331,661.90	\$ 7,814,609.15	\$ 7,503,951.53	\$ 254,120.18
PANTOPRAZOLE SODIUM	GENERIC	\$ 9,312,241.38	\$ 419,208.02	\$ 77,878.76	\$ 341,387.34
VICTOZA	BRAND	\$ 8,580,440.86	\$ 6,682,899.98	\$ 6,148,150.39	\$ 521,385.76
REVLIMID	BRAND	\$ 7,850,452.16	\$ 6,294,802.87	\$ 6,123,950.47	\$ 121,868.32
TALTZ	BRAND	\$ 7,803,861.57	\$ 6,022,732.46	\$ 5,587,346.29	\$ 417,629.13
TRESIBA	BRAND	\$ 7,669,919.08	\$ 5,967,037.41	\$ 5,386,347.69	\$ 573,632.03
ONDANSETRON	GENERIC	\$ 7,324,283.03	\$ 297,250.60	\$ 100,588.01	\$ 197,910.50
GABAPENTIN	GENERIC	\$ 7,264,734.24	\$ 619,733.83	\$ 206,506.67	\$ 413,288.50
XELJANZ XR	BRAND	\$ 7,253,281.16	\$ 5,917,043.83	\$ 5,367,362.31	\$ 428,019.99

SERTRALINE HYDROCHLORIDE	GENERIC	\$ 7,197,949.88	\$ 625,452.86	\$ 80,489.85	\$ 544,962.70
JANUVIA	BRAND	\$ 7,085,892.44	\$ 5,352,226.32	\$ 4,666,459.39	\$ 685,878.72

* To be included in this table, at least 20 prescriptions for the drug must exist in the database.

2021 Q3 RX Counts by Plan / Product Type

Plan Type	Plan Description	Product Type	Product Description	RXcount	Charged Per Script	Allowed Per Script	Paid Per Script	Mbr Resp Per Script
2	PPO	1	Medical/Health	2,977,427	\$ 363.55	\$ 195.37	\$ 173.10	\$ 22.21
7	Qualified High Deductible Plan	1	Medical/Health	665,331	\$ 402.53	\$ 218.39	\$ 163.30	\$ 52.88
4	POS	1	Medical/Health	341,645	\$ 302.05	\$ 161.11	\$ 144.98	\$ 16.13
3	HMO	1	Medical/Health	29,173	\$ 524.13	\$ 294.02	\$ 264.38	\$ 30.74
7	Qualified High Deductible Plan	2	Ancillary Drug	281	\$ 482.04	\$ 247.45	\$ 226.67	\$ 20.78

2021 Q3 PMPM RX Costs

	Member Months	Allowed	Average PMPM
Age <= 14	633,924	\$ 36,554,301.01	\$ 57.66
Age 15-24	568,949	\$ 62,586,254.23	\$ 110.00
Age 25-44	1,291,178	\$ 223,124,354.01	\$ 172.81
Age 45-64	1,334,235	\$ 408,641,909.34	\$ 306.27

Average Allowed Charge PMPM by Age Group

